This trial is testing a new cancer drug, enfortumab, alone and in combination with other cancer drugs. The trial will start with testing enfortumab by itself (monotherapy), and additional groups (cohorts) may be added later as new drug combinations are found.
1 Primary · 0 Secondary · Reporting Duration: 12 months
34 Total Participants · 1 Treatment Group
Primary Treatment: Enfortumab vedotin · No Placebo Group · Phase 2
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: